Glucotrack, Inc. — Form 8-K
Filed July 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Glucotrack, Inc. (public market value ~$5.4M) agreed to merge with Lokahi Therapeutics, Inc. (private) via a forward triangular merger. Lokahi shareholders receive 90% of post-Closing equity (on fully diluted basis, including Bridge Shares and PIPE Shares, capped at 10% floor for Glucotrack existing shareholders) as Acquiror Common Stock and Series A Convertible Preferred Stock (~100:1 conversion ratio). Lokahi's $7M promissory note is assumed by the Company. Up to $30M private placement targeting minimum $10M at PIPE Initial Closing. Operating Business ring-fenced in subsidiary; Lokahi operates Surviving Corporation during 12-month interim period.
Why this rating
Reverse merger is transformational for $5.4M public shell: acquires operating therapeutic device company (Glucotrack CBGM), dilutes existing shareholders to ~10% floor, requires major capital raise ($7-30M), complex financing/governance structure. Material relative to tiny public vehicle.
See more from July 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.